Please use this identifier to cite or link to this item:
Title: Omalizumab: what benefits should we expect?
Authors: Giménez-Arnau, Ana
Velasco, Manel
Armario Hita, Jose Carlos
Labrador-Horrillo, Moises
Silvestre Salvador, Juan Francisco
Keywords: chronic urticaria;efficacy;health care;omalizumab;safety
metadata.dc.subject.mesh: Adult
Anti-Allergic Agents
Chronic Disease
Emergency Service, Hospital
Health Care Costs
Middle Aged
Office Visits
Primary Health Care
Retrospective Studies
Treatment Outcome
Issue Date: 2016
Abstract: Chronic spontaneous urticaria (CSU) is a skin disease characterised by wheal appearance, swelling, itching, and painful skin. Omalizumab has been used for CSU treatment demonstrating good efficacy. To investigate the efficacy and safety of omalizumab treatment in CSU patients in real-life practice. A retrospective analysis was performed on 38 patients suffering from CSU who received 300 mg of omalizumab every four weeks. After omalizumab treatment, 68.4% of patients showed a complete response (UAS7 = 0). All the patients were able to stop treatment with corticosteroids, cyclosporine, and anti-leukotrienes, and only 39.5% of patients remained on anti-histamines. Omalizumab treatment led to a 96% and 65% decrease in emergency room and primary health care visits, respectively, as well as a reduction in the direct costs associated with the disease. No omalizumab-related adverse events were reported. Omalizumab exhibits good efficacy in alleviating the symptoms of CSU, leads to a decrease in concomitant medication use, restores patients' quality of life, and has economic benefits by reducing disease-related health care costs.
metadata.dc.identifier.doi: 10.1684/ejd.2016.2809
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.